NEW YORK, February 22, 2017 /PRNewswire/ --
Stock-Callers.com takes a closer look at the following Medical Laboratoriesand Research stocks: Exact Sciences Corp. (NASDAQ: EXAS), Agilent Technologies Inc. (NYSE: A), PerkinElmer Inc. (NYSE: PKI), and ICON PLC (NASDAQ: ICLR). These companies are part of the Healthcare sector which was mostly higher in late afternoon trading
On Tuesday, shares in Madison, Wisconsin headquartered Exact Sciences Corp. recorded a trading volume of 14.77 million shares, which was above their three months average volume of 2.34 million shares. The stock ended the day at $22.41, jumping 12.56% from the last trading session. The Company's shares have surged 23.88% in the last one month, 53.28% in the previous three months, and 67.74% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 34.21% and 46.87%, respectively. Furthermore, shares of Exact Sciences, which focuses on developing products for the early detection and prevention of various cancers, have a Relative Strength Index (RSI) of 79.59.
On February 21st, 2017, Exact Sciences announced that the Company generated revenues of $99.4 million and completed approximately 244,000 Cologuard tests during the year ended December 31st, 2016. The Company's full-year 2016 revenues and Cologuard test volume grew 152% and 135% from full-year 2015, respectively.
Yesterday, research firm The Benchmark Company upgraded the Company's stock rating from 'Hold' to 'Buy' while revising its previous target price from $17 a share to $27 a share. Visit us today and download your complete report on EXAS for free at:
Santa Clara, California headquartered Agilent Technologies Inc.'s stock saw a slight drop of 0.54%, finishing yesterday's session at $51.35 with a total trading volume of 2.04 million shares. The Company's shares have gained 7.83% in the last month, 12.10% over the previous three months, and 12.71% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 7.38% and 11.62%, respectively. Additionally, shares of Agilent Technologies, which provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide, have an RSI of 65.57.
On February 14th, 2017, Agilent reported revenue of $1.07 billion, up 3.8% on a y-o-y basis for Q1 FY17. The Company's Q1 FY17 GAAP net income was $168 million, or $0.52 per share, compared to GAAP net income of $121 million, or $0.36 per share, for Q1 FY16. The complimentary research report on A can be accessed at:
Shares in Waltham, Massachusetts headquartered PerkinElmer Inc. ended the session 0.50% lower at $55.66. The stock recorded a trading volume of 592,384 shares. The Company's shares have gained 7.64% in the last one month, 9.41% in the previous three months, and 6.87% on an YTD basis. The stock is trading 4.82% above its 50-day moving average and 4.38% above its 200-day moving average. Moreover, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide, have an RSI of 65.37.
On January 27th, 2017, PerkinElmer's Board of Directors declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 10th, 2017, to all shareholders of record at the close of business on April 14th, 2017.
On February 03rd, 2017, research firm Bank of America/ Merrill downgraded the Company's stock rating from 'Neutral' to 'Underperform'. Register for free on Stock-Callers.com and download the PDF research report on PKI at:
At the closing bell on Tuesday, Dublin, Ireland headquartered ICON PLC's stock declined 0.99%, finishing at $84.83. A total volume of 497,078 shares was traded, which was above their three months average volume of 388,790 shares. The Company's shares have advanced 5.94% in the last month, 9.85% over the previous three months, and 12.81% on an YTD basis. The stock is trading 5.79% and 12.45% above its 50-day and 200-day moving averages, respectively. Additionally, shares of ICON, which provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the US, and internationally, have an RSI of 55.13.
On February 15th, 2017, Iconix announced that it plans to report its Q4 2016 and full year 2016 financial results after the close of market on February 22nd, 2017. A conference call to discuss the financial results will be held at 5:00 PM ET on the same day. Get free access to your research report on ICLR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...View All